Ina Research is a contract research organization (CRO). They provide non-clinical study for pharmaceuticals, medical devices, regenerative medicine products, agricultural chemicals, and chemical substances. They are fully compliant with the latest regulations.
This page showcases key features of Ina Research’s non-clinical service, examples of disease models, and related information.
We hope that you can use this information for a reference when selecting a trusted CRO partner.
Ina Research performs non-clinical testing for pharmaceuticals, medical devices, and agrochemicals in accordance with Good Laboratory Practice (GLP) standards.
They have earned a strong reputation for reliability in efficacy, pharmacology, and safety evaluations, maintaining strict quality control under the latest regulatory guidelines.
Specialized pharmacological studies related to the central nervous system and ophthalmology are also available.
The company offers a wide range of specialized disease models for pharmacological evaluation, particularly in central nervous system and ophthalmology.
These models enable precise assessment of new drug efficacy for target diseases.
Ina Research has also developed proprietary models used in studies for liver diseases and fibrosis.
They provide comprehensive non-clinical service — from screening to Phase I clinical ready — can be achieved as little as in eight months.
their experienced science team can provide rapid, efficient support to deliver high-quality data on schedule.
It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.
However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.
Below are some examples of disease models offered at Ina Research.
With the growing number of patients requiring dialysis, animal models of renal failure are essential for studying disease onset, progression, and potential therapeutic agents.
Ina Research conducts pharmacological study with surgically induced partial nephrectomy models.
Long-term diabetes can impair kidney filtration function, leading to diabetic nephritis. As the condition progresses, it can cause edema and hypertension and ultimately require dialysis.
Ina Research has an established diabetic nephritis model to evaluate therapeutic agents for nephropathy.
This model is for investigating the mechanisms of onset and progression of glomerulonephritis.
Clients can now research in molecular and genetic-level factors in nephritis.
No case studies are currently listed on the official website.
Ina Research is a contract research organization expanding its expertise across safety and efficacy evaluation in pharmaceuticals, food, chemicals, and medical devices, while continuously enhancing its unique capabilities.
| Address | 2148-188 Nishi-Minowa, Ina City, Nagano Prefecture, Japan |
|---|---|
| Tel | 0265-72-6616 |
| Website | https://www.ina-research.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.